SUVEN LIFE SCIENCES TO PRESENT FIVE SCIENTIFIC POSTERS AT AAIC-2026

Suven Life Sciences announced its participation at the Alzheimer's Association International Conference (AAIC) 2026 in London. The company will present five scientific posters, including updates on its global Phase-3 Masupirdine clinical program and Usmarapride Phase-2 clinical development program. Presentations will cover Masupirdine for agitation in Alzheimer's dementia, a Muscarinic 4 positive allosteric modulator (SUVN-L1101142), and safety/pharmacokinetics of SUVN-I6107. Updates on Usmarapride for cognitive disorders and SUVN-N9503012 for neurodegenerative disorders will also be presented. The conference is a key event for advancing dementia science and clinical practice.

Suven Life Sciences Limited

Open attachment

← Back to feed